There is still an unexplored potential for exhaled nitric oxide (NO) in many clinical applications. This study presents an overview of the currently available methods for monitoring NO in exhaled breath and the use of the modelling of NO production and transport in the lung in clinical practice. Three technologies are described, namely chemiluminescence, electrochemical sensing and laser-based detection with their advantages and limitations. Comparisons are made in terms of sensitivity, time response, size, costs and suitability for clinical purposes. The importance of the flow rate for NO sampling is discussed from the perspective of the recent recommendations for standardized procedures for online and offline NO measurement. The measurement of NO at one flow rate, such as 50 ml s −1 , can neither determine the alveolar site/peripheral contribution nor quantify the difference in NO diffusion from the airways walls. The use of NO modelling (linear or non-linear approach) can solve this problem and provide useful information about the source of NO. This is of great value in diagnostic procedures of respiratory diseases and in treatment with anti-inflammatory drugs.
Introduction
The rapid oxidation of nitric oxide (NO) in biological tissue with a half-life of few seconds explains the problem of measuring NO. Several indirect assays, e.g. cGMP, nitrite or citrulline conversion, have been used for the measurement of NO production [1] . In search of the role of NO during hypoxic pulmonary vasoconstriction, it was necessary to find a way to detect NO in exhaled breath. NO is a gas with low solubility in aqueous solutions; therefore it escapes into the airways and is transported in the exhaled gas from the alveolar region. On the way out it collects additional NO diffusing from the airway walls.
The chemiluminescence analyzer adopted from atmospheric NO measurement [2] allowed the detection of NO in human breath [3] . Moreover, using NO analysers with fast enough response time showed that NO peaked in the beginning of the exhalation, which is in contrast to the exhaled CO 2 that reaches its en tidal value after the inhaled gas from the anatomic dead space has been washed out. It was concluded that most of the NO release was from the airways. The new lung biomarker fitted well with the knowledge about the airway epithelium [4] and injury by eosinophils in asthma [5] ; and soon it was discovered that exhaled NO was increased in asthma [6, 7] . Exhaled NO became an inflammatory marker [8] and a new research field was born.
In the last two decades of NO research, exhaled NO has been shown to be altered in different respiratory diseases [9, 10] , and the clinical usefulness was shown with treatment [11] and progress of disease [12] . Today there are different techniques to detect NO; besides chemiluminescence, electrochemical sensors and laser techniques are also used.
Theoretical models have been introduced to understand the partition of NO production between alveolar regions and conduction airways. Despite the progress made in understanding the role of NO in clinical research, numerous questions still need to be answered and findings validated. Very often, NO modelling covers almost all NO research topics. Therefore the search for suitable methods to detect NO in exhaled breath, NO measurement procedures and modelling of NO production and transport in the lung is strongly motivated and will be the main topic of this study.
Current technologies
The interest in measuring NO in exhaled breath was not only driven by its potential in disease diagnosis and management, but also by the technology available for NO detection. Currently, the chemiluminescence devices are considered as the standard technique; and all the later developed detection methods for measuring NO, such as electrochemical and laserbased detection, are introduced in comparison to it. Here, the working principle of these three technologies is briefly described and their pros and cons for clinical applications have been discussed.
Chemiluminescence analyzers
Within the chemiluminescence detection, NO is indirectly measured by means of light generation due a chemical reaction with ozone (O 3 ):
This is a two stage reaction whereby NO with O 3 produces excited-state nitrogen dioxide (NO 2 * ), that emits a photon upon de-excitation to the ground state. The emitted light (at >600 nm wavelength) is detected with a photomultiplier tube or solid state device that provides a signal directly proportional to the NO concentration. In general, these analysers are bulky (20-50 kg), not quite user friendly, need external clean air for ozone generation inside the instrument and vacuum pump system which makes them expensive as well. Additionally, an annual check of chemical reaction converters and ozone generator and its peripheral components is needed to ensure supply of sufficient ozone for the chemical reaction with NO and prevention of increase in the noise level.
Other gases in breath can disturb the chemical reaction of NO with O 3 and may interfere with the accurate analysis of nitric oxide [13] , especially quenching effects due to carbon dioxide and water [14] .
If all the requirements are fulfilled, the chemiluminescence instruments can be very sensitive, with detection limits at ppbv-level (parts per billion, 1:10 9 ) (1.5 ppb for NIOX from Aerocrine, Solna, Sweden) or even lower (0.1 ppb for CLD 88 from Eco Medics, Duernten, Switzerland; 0.5 ppb for Sievers NOA 280i from GE Analytical Instruments). The response time of such a system is fast, between 0.5 and 0.7 s.
In addition to the size and investment cost limitations, the chemiluminescence analysers suffer from drift. To compensate for the drift, frequent calibration is required, e.g. daily or each day the instrument is used for measurements. Calibration can be performed with high NO concentration in the tens of ppmv level or hundreds of ppb that is close to the normally measured NO values. A yearly technical service is recommended by each manufacturer which requires the instrument to be shipped to the dealer or support centre. Subsequently the running costs will increase.
These drawbacks have limited the use of chemiluminescence analysers in routine clinical applications or home monitoring.
Electrochemical sensors
Electrochemical sensors have been used, for example in measuring O 2 , for many years. Basically, an electrochemical sensor transforms the concentration of a gas into other detectable electrical signals. The target gas undergoes a chemical reaction with the active sensing material, and in the presence of an electrical circuit generates a measurable physical change.
For the fractional exhaled NO (F E NO) detection, amperometric sensors, in which the measurand is current, were developed by Aerocrine (NIOX MINO) [15] and recently by Bedfont (NObreath) [16] . The sensors were included into a hand-held device weighing less than 1 kg and allowing a sampling rate of 50 ml s −1 . Their detection limit of 5 ppb is an order of magnitude less than that of the chemiluminescence analyzers, which is good for an electrochemical sensor. Numerous studies reported the performances of the new electrochemical devices in comparison with the chemiluminescence analysers. A summarized overview can be found elsewhere [17] . The high correlations (95%) obtained for F E NO values between different sensors, in combination with the portable characteristic, were sufficient for the first commercially available portable device (NIOX MINO) to get the FDA approval for clinical work in 2003.
In contrast to chemiluminescence analysers, the NIOX-MINO does not allow for pre-test calibration. The electrochemical device uses a sensor which needs to be replaced after 100-300 measurements.
One might consider that in the absence of regular calibration, the performances of such device could change over time or when a sensor is replaced. Using multiple sensoranalyser combinations at baseline, after one and two months of use, Taylor et al found that the reproducibility of the measurements is affected for frequently used devices (up to 279 times), although the difference (<10 ppb) was classified as not clinically important. The authors underlined that an acceptable threshold for reproducibility needs to be considered ( ± 5 ppb or ± 10 ppb).
In general the F E NO measured with the NIOX-MINO device were systematically higher than those measured with other methods [18] , while the NObreath device was consistently lower than the chemiluminescent analyser [19] . Overall, it has also been reported that the coefficients of variation (CVs) and limits of agreement are greater when measuring high rather than low F E NO values with the NIOX-MINO [17, 20, 21] . In comparison with the NObreath, the Figure 1 . Schematic representation of a laser-based sensor. It consists of a laser source, a cell containing the gas sample where the light is absorbed or where its polarization changes, and a detector for measuring the light intensity alteration in the presence of gas absorbent.
NIOX-MINO does not record F E NO from poor exhalation manoeuvres, an important detail while measuring F E NO in children. This could be the reason why some children were not able to use the NIOX-MINO. The F E NO measurements in children with NIOX-MINO showed very good repeatability, supporting the manufacturer recommendation that only one test value is required. The NObreath sensor had a good, although not adequate, repeatability; the subject had to provide at least three exhalations for consideration [18] .
In conclusion, as many authors have already mentioned, the F E NO values obtained with the portable electrochemical sensors are reliable since the difference that resulted from comparison with the standard chemiluminescence technique of 4 ppb up to 10 ppb is clinically not relevant. These in combination with their acceptable detection limits of a few ppb and especially the small size, are major considerations for indicating the electrochemical sensors suitable for clinical practice. Although the investment costs are lower for the electrochemical sensors than for the chemiluminescence analysers, additional costs for consumables have to be considered when using the portable ones. For example, the cost for a single measurement using the NIOX-MINO sensor is about $10 in USA and € 18 in the Netherlands.
New generations of sensors continue to be developed, either with enhanced capabilities for miniaturization like the smart breath health diagnostic system [22] based on smart solid-state microsensor technology or using the laser-based optical methods as further described in the next section.
Laser-based sensors
Next to the chemiluminescence and electrochemical devices, optical sensors were also developed for the detection of NO concentrations at low ppb level. These are based on different laser technologies and detection methods. Typically an optical sensor detects any change in light intensity or polarization when the light is interacting with targeted molecules. A simple schematic is provided in figure 1 . It includes three main elements: the laser source, which produces the light interacting with the molecule; the gas cell containing the sample, which analyses where the light will experience attenuation and/or polarization changes; and the detection system which is able to sense these modifications, for example a simple photodetector to measure intensity variation.
Optical techniques used to assess NO concentrations have been known for decades; however, their successful application for the detection of low concentrations has only been possible over the past few years, thanks to the fast development of semiconductor lasers and photodetectors. For years, optical laser-based sensors were known to be selective, i.e. only sensitive to the target compounds, and reliable in terms of accuracy and precision. In the 90s, the chemiluminescence analysers were considered as 'gold'-standard systems to assess exhaled NO in human breath. Despite the drawbacks of chemiluminescence sensors, optical laser-based systems were far from being considered for bio-medical applications. High sensitivity combined with fast response time in a compact design represented a great challenge to be achieved.
To reach the highest sensitivity in absorption spectroscopy, the light source should probe the strongest absorption feature of the investigated molecule. In the case of NO, the fundamental and strongest absorption band is centred in the mid-infrared region at 5.3 μm (spreading from 5.1 to 5.7 μm). In this spectral range several other gases, like CO 2 and H 2 O, are also absorbing, and therefore only some specific absorption NO lines can be targeted to avoid any interferences with these compounds. Consequently, the main challenge is the availability of a laser source able to emit light at such wavelength, which in turn limits the development of laserbased NO sensors. Before 2000, only three types of lasers were able to emit light in such a good wavelength region [23] : CO lasers, sources based on nonlinear optical parametric frequency conversion and lead-salt diodes. Among these, the latter, although needing liquid nitrogen for cooling, had the potential to be integrated into a commercial sensor.
The first sensors employed for breath analysis based on laser diodes made use of direct absorption spectroscopy [24, 25] . The method is known as TDLAS (tunable diode laser absorption spectroscopy). The laser beam was passed through a multipass-cell where the beam experienced several reflections, increasing the interaction distance with the sample and therefore the absorption signal. Offering an absorption path length of several hundred metres, the multipass-cell affords a compact design with a footprint less than 50 cm. TDLAS was first used for simultaneous CO and CO 2 measurements in human breath, but the detection of NO in breath was reported a few years later [26] . TDLS reached sensitivity in the ppb range and was, therefore, suitable for breath measurements. The laser and detector used at that time had to be cooled to extremely low temperatures, between 10 and 200 K. Therefore, the system was placed into a nitrogen cryostat and was not convenient to operate outside the laboratory. The source itself also suffered from spectral degradation and reliability problems over time.
At the same time, another detection method was proposed for breath analysis. In this method instead of measuring the absorption of the light, Faraday rotation spectroscopy (FRS) detects the rotation of the polarization of light when it goes through a sample placed in a magnetic field [27] . This detection method is extremely selective as it is able to detect only paramagnetic molecules, such as NO [28] . Moreover, for breath analysis, FRS was very attractive as other compounds present in breath cannot disturb the detection of exhaled NO concentration. FRS used for on-line breath analysis was able to achieve a detection limit of 1 ppb in 0.3 s [29] . The compact single pass-cell used in such method has a response time of only 0.8 s with a flow rate of 800 ml s −1
. However, despite its capability to follow NO concentration of each breathing cycle, the use of a bulky, liquid nitrogen cooled CO laser did not allow applications outside the laboratory.
Recent advances in the fabrication of mid-IR lasers opened new opportunities for compact and stand-alone NO sensors. A new semiconductor laser source, the quantum cascade laser (QCL), was proposed in 1994 [30] . Over time it appeared suitable and reliable enough for optical gas sensors to work in the mid-infrared region. Working at cryogenic temperature at the beginning, QCLs are now commercially available sources for almost any mid-infrared wavelength working at room temperature and offer good performances for spectroscopy, i.e. single mode operation and fast wavelength scanning. Over time, they were combined with several spectroscopic detection methods and applied for breath analysis, including NO detection. Several spectroscopic methods have been proposed over the past 10 years, each of them offering different possibilities in terms of response time, sensitivity, reliability, practical operation and portability.
Following TDLAS development, QLCs were coupled with multipass-cells [31] [32] [33] [34] [35] . The first demonstrations were done using continuous wave N 2 -cooled sources [31, 36] or thermo-electrically cooled pulsed laser [32] . With direct absorption detection, the sensitivity was limited to 3 ppb with an integration time of 200 s [31] . Later on, the wavelengthmodulation technique was implemented to increase the signalto-noise ratio achieving a sensitivity of 0.2 ppb in 30 s [33] .
Further improvements in the QCLs allowed them to work at room temperature at higher laser power; sub-ppb detection of NO in 1 s averaging was achieved [33, 34] . These sensors were successfully applied for NO studies in life sciences [37] as well as breath analysis [38] [39] [40] .
Other spectroscopic methods than the multipass-cell have been proposed, taking advantage of QCLs development. The ones most related to the multipass-cell configuration are based on high-finesse optical cavities. In comparison, the high finesse optical cavities use very high reflectivity mirrors (transparent dielectric mirrors with a reflectivity of 99.99% instead of massive gold mirrors of 98% for a multipass configuration). Thus, a very long optical interaction can be reached, i.e. up to several kilometres instead of several hundred metres, improving the sensitivity. There are several approaches for using high-finesse cavities, each with their own name. The ones reporting NO detection are: cavity ring down spectroscopy (CRDS) [41] , cavity enhanced absorption spectroscopy (CEAS) [31] and integrated cavity output spectroscopy (ICOS) [42] [43] [44] . Based on high-finesse cavities, NO-sensors were successfully implemented to measure NO in breath, either with off-line or on-line breath sampling. The detection limit of these schemes was sub-ppb in 1 s. The spectroscopic methods showed better stability to temperature variation compared to multipass configurations. However, high finesse cavity-based systems were very sensitive to any misalignment of the laser light and required technical skills to be operated. Only the ICOS method in its off axis configuration was proved to be technically less demanding for a transportable sensor [45] .
As QCLs are perfect candidates for integrated detection systems, two other techniques were proposed for NO sensing at low concentration: Faraday rotation spectroscopy (FRS) and photoacoustic spectroscopy (PA), which were implemented for the detection of low-NO concentration. However, despite offering sufficient quality for breath analysis, no clinical study on breath analysis has been performed so far with such sensors.
Till recently, FRS methods have been applied successfully for on-line NO detection with QCLs replacing CO lasers [46] [47] [48] [49] . FRS sensors have been offering sub-ppb detection limit with sub-second response time and were successfully implemented in measuring biogenic nitric oxide concentration [50] . However, to achieve a sensor suitable for clinical breath study, FRS sensors have to deal with technical problems due to the generation of the magnetic field, i.e. high power consumption and shielding of the modulated magnetic field.
Photoacoustic spectroscopy is a technique that assesses the concentration of the gas of interest by measuring the amplitude of acoustic waves produced by the absorption of modulated laser radiation. The light absorption is not directly measured, but pressure variation of the gas due to the transient temperature effect is detected with a sensitive microphone. In 2001 it was used with QCLs for ammonia detection [51] , and later on a detection limit of 500 ppb for NO was reported [52] , which was not sufficient for NO measurements. This limitation was explained by the lack of power of QCLs, as in PAS the signal is directly proportional to the light intensity. However, the compact photoacoustic cell does not require careful alignment, which is a great advantage for a commercial device.
Taking advantage of PAS, a novel approach 'quartzenhanced photoacoustic spectroscopy (QEPAS)' to overcome the lack of intensity in photoacoustics was proposed in 2002 [53] . Recently, QEPAS was able to reach a NO detection limit of 15 ppb within 5 s, and from this point it started to become attractive for medical applications.
Clinical applications of laser-based detectors.
The chemiluminescence and electrochemical technologies were already available when their use for analysing exhaled NO began. They were directly adopted in clinical trials and the results were compared. This was not, however, the case for the laser-based detectors since these have to be developed according to the availability of the laser sources and only then can be applied in the medical field [54] .
Nowadays, two commercial NO laser-based sensors are available for clinical work based on multipass-cell configuration. One was developed at EKIPS Technologies using lead-salt diodes with a closed cycle refrigerant system instead of liquid nitrogen cooling, allowing a detection limit of 1.5 ppb in 4 s [36, 55] . The instrument, 'the Breathmeter', was used to determine the statistical distribution of exhaled NO in a clinical screening including 769 subjects (both children and adults) and tried to set the cut-off values to indicate the presence of airways inflammation. The device allows internal calibration and can measure, with one laser, both NO and CO 2 ; the latter being used for checking the proper exhalation. The second commercial system includes two QCLs for multicomponent analysis (NO, CO 2 with one QCL and CO and N 2 O with another QCL) and can detect less than 0.3 ppb of NO within 1 s [34] . The instrument has a large size since it includes the two QCL-based detectors for gas detection (17 racks of 25 kg each) and a breath sampling system for multiple exhalation flows with the required pumping system. This was the first QCL-based system used in larger studies of exhaled NO, particularly in asthma and chronic obstructive pulmonary disease (COPD) [39] . The data showed good comparison with the exhaled NO levels sampled at 50 ml s −1 reported in adults and healthy children [56] . Using NO modelling [57] , the authors found higher airways fluxes for severe asthma and during exacerbation in paediatrics and higher alveolar concentrations for asthma and COPD adult patients as compared to the controls, similar to the other previous reports [58, 59] .
Other schemes using QCLs, although not commercially available, were used for small clinical trials and have been compared with the chemiluminescence and/or electrochemical devices. A QCL-based ICOS scheme showed good agreement with the chemiluminescence technique within 1.5 ppb [44] . Similarly, the F E NO values measured with a QCL-based sensor using multipass-cell from 20 children diagnosed with asthma and treated with inhaled corticosteroids were found clinically acceptable within 1.1 ppb when compared with the chemiluminescent sensor and within 1.7 ppb when compared to the electrochemical sensor [40] . Moreover, the sensor was used in combination with external breath samplers [40, 60] to allow single exhalation sampling at different flow rates. The combination was tested on healthy subjects and the extended NO parameters, i.e. NO airway flux (J aw NO), alveolar NO (C A NO) airway wall concentration of NO (C aw NO) and airway compartment diffusing capacity of NO (D aw NO) were in good agreement with the previously reported values [61] . The performance characteristics for the three types of NO analysers are listed in table 1.
Standardization of the NO measurement
The chemiluminescence analysers for environmental use were applied for the early measurement of exhaled breath in animals and humans. In the first publication of exhaled NO in humans by Gustafsson et al, the instrument had a sampling rate of 100 ml min -1 , a detection limit of 2 ppb and was calibrated with a certified gas of 250 ppm NO in N 2 [3] . The typical NO level in exhaled human breath was about 8 ppb, i.e. half of the values obtained from rabbits. Soon after this, NO concentrations in asthmatics were reported [6, 7] . Alving et al used tidal breathing through the nose or mouth and found 30 ppb in control subjects and 2-3 fold increase in asthmatics [6] . Kharitonov et al used a slow vital capacity manoeuvre over 30-75 s into Teflon tubing, from where the analyser sampled the gas continuously [7] . Three successive recordings were made and the results were displayed on a chart recorder and compared with the signal of the calibration mixture of 89 ppb in N 2 . Control subjects were found to have a peak of 80 ppb, untreated asthmatics 283 ppb and treated asthmatics 101 ppb [7] . This discrepancy of a tenfold increase in control subjects compared to the first report could be due to several causes, i.e. the analyzer detection limit and response time, and accuracy of calibration and the different sampling approaches. In 1996 it was found that exhaled NO was flow dependent [62] . This discovery led to the first task force on NO measurement by the European Respiratory Society and recommendations were soon published [63] . Similar results were also obtained in North America independently by Silkoff et al [64] and an American task force was set up in 2002 and recommendations were published [65] . In 2005 a European/North American joint taskforce updated the previous recommendations and agreed to measure NO at a flow rate of 50 ml s −1 (F E NO 0.05 ) in order to compare data from different groups [66] . Therefore, the flow rates should be given in the publication of scientific reports about exhaled NO.
To facilitate the performance of exhalation, a restrictor can be used; however, it is necessary to know at what flow rate the patient is actually blowing. The importance of exact flow rate can be demonstrated in a patient with atopic asthma before and after treatment [67] . Due to the steepness of the curve, NO can vary between 98 and 71 ppb if the flow rate is 40, respectively 60 ml s −1 instead of 50 ml s −1 ( figure 2) . If the effects of treatment are to be taken into account it is important to compare the NO concentration at the same flow rate. This is also the case in the comparison of different technical devices or technologies. The curve of exhaled NO concentration versus flow rate for one atopic asthmatic subject before and after treatment, and control subjects, respectively. In control subjects, the use of a lower flow rate of 40 ml s −1 gives 3 ppb higher values as compared to 50 ml s −1 (a). In the asthmatic patients this change in flow rate will result in a difference of 7 ppb after treatment (b) and 16 ppb without treatment (c) [9, 61] .
Recommendations for standardized procedures for online and offline NO measurement have been published [66] . Briefly, the subject inhales NO free air, with an extended inhalation not necessary to a vital capacity [68] . A restrictor will guide the subject to a smooth exhalation to achieve and maintain 50 ml s . A minimum airway pressure of 5 cm H 2 O must be present for closure of the velum and to avoid nasal NO contamination. At least two NO plateau values that agree within 10% of each other should be sampled. Additional NO measurements might be necessary due to instrument variability and patient flow rate control variability. The mean value of the NO concentrations is then calculated.
Nitric oxide measurement at one flow rate such as 50 ml s −1 , cannot determine the NO production site of the respiratory system nor quantify the difference in NO transfer from the walls of conduction airways. F E NO 0.05 has been shown to give lower values in healthy children (10 ppb) [69] compared to healthy adults (18 ppb) [61] . In asthmatics, the NO levels were increased 2-3 fold [6, 7] . Therefore NO was used to assess the inhaled corticosteroid treatment [70] [71] [72] . However, recently it was concluded that defining the dose of inhaled corticosteroids based on exhaled NO cannot be routinely advocated [73] . One reason for this could be that both non-atopic and atopic asthmatics were recruited in these studies. Atopic asthmatics have increased values compared to non-atopic asthmatics [74] [75] [76] . There are also additional reasons that can be explained by using the NO modelling from the lungs.
Modelling NO release from the lungs
Asthma is an obstructive inflammatory disease characterized by recurrent attacks and variations in frequency and severity from person to person. In severe asthma the peripheral airways are affected and treatment given by inhalation may not reach this site. A biomarker such as NO would be ideal to follow the treatment effects of inhaled corticosteroids. It is therefore desirable to have insight into how widespread the inflammation is. Also in diseases where there are alveolar engagements with increased alveolar/peripheral NO, such as COPD [74] and systemic sclerosis [77] , it is interesting to follow the progress of the disease. Nitric oxide is mostly produced in the airways, and the contributions from the alveolar site and the peripheral airways are less. During the exhalation a bolus of gas with low concentration moves up through the airways and picks up NO on its way. This was the basis for the application of Fick's first law of diffusion [78] on modelling NO production in the respiratory system. With this information a two-compartment model (2CM) was created. Several research groups came up with different calculations using both low and high flow rates with linear and nonlinear NO models [11, 68, 79, 80] .
The different models have been extensively reviewed and the readers are referred to George et al and Högman et al for further reading [9, 81, 82] . The linear model can calculate alveolar/peripheral NO (C A NO) and airway flux of NO (J aw NO). Additional mathematical calculations with NO measurements obtained at low, medium and high flow rates, the nonlinear model enables separation of the airway wall concentration of NO (C aw NO) and airway compartment diffusing capacity of NO (D aw NO). The abbreviations of the NO parameters are given in table 2.
Linear model
NO values at multiple constant exhalation flow rates between 100 and 500 ml s −1 are measured and the volume of exhaled NO is plotted versus the flow rates. The slope and the intercept of the resulting linear regression line provide an estimate of C A NO and J aw NO, knowing the elimination rate of NO from the breath during exhalationV NO and the exhalation flow ratė V E (equation (1)). The r-value of the line gives the qualities of Table 3 . NO measurement and calculated NO parameters in healthy children and adults from Sepponen et al [69] and Högman et al [61] . Data are given in mean ± SD (median).
NO parameters
Children (n = 66) Adults (n = 89) 
With this linear model of NO production it is possible to differentiate between alveolar and bronchial inflammation [83, 84] . In severe and nocturnal asthma, Lehtimäki et al have found increased levels of C A NO [85, 86] . In smokers the J aw NO is decreased and increases with smoking cessation [87] . However, in ex-smokers the J aw NO remains lower than in never-smokers [88] . In COPD the J aw NO can vary with smoking status [89] , but the major finding in this group of patients is the increase in C A NO [74, [89] [90] [91] . The diagnostic value of C A NO to detect interstitial lung disease (ILD) has been investigated in patients with systemic scleroderma. Tiev et al found that the relationship between D LCO impairment, the presence of ILD on lung CT scan and C A NO levels, was able to identify a C A NO cut-off value [92] . C A NO levels higher than 4.3 ppb were associated with early impairment of gas exchange (defined as decreased diffusing capacity of the lung for CO, D LCO ), and patients with C A NO levels >10.8 ppb were very likely to have ILD. In a three year follow-up study of these patients it is clearly concluded that a cut-off C A NO value of 5.3 ppb will predict the risk of subsequent lung function deterioration or death in patients with scleroderma [12] .
Nonlinear model
With the nonlinear model NO values at multiple constant exhalation flow rates between 10 and 500 ml s −1 are obtained and the volume of exhaled NO is plotted versus the flow rates. The equation of the curve gives the solution of C A NO, C aw NO and D aw NO. The true J aw NO can then be calculated. The Högman and Meriläinen algorithm uses three flow rates: 10, 100 and 500 ml s −1 [74] . These flow rates are under investigation since the low flow rate is hard to perform for both children and adults and the high flow rate puts demand on the NO analyser making a plateau difficult to obtain. Taking into account the contribution of axial back diffusion of NO [57, 93] , one should use flow rates at the higher end between 350 and 400 ml s −1 . The low flow rate of 10 ml s −1 can be replaced by 20 ml s −1 . In many studies control subjects are included, but there are only two studies so far that have focused on gathering reference values for NO parameters in health: one in children [69] and one in adults [61] . The C aw NO and J aw NO appear to be lower in children, but D aw NO and C A NO are somewhat higher (table 3) . Comparisons of the different models have been published [82] and the nonlinear model has been found to provide a better fit to experimental data and is, therefore, suggested to be the preferred method so far [94] . The advantage of multiple flow analysis relies on the simplest calculations and may therefore be considered most robust [95] .
However, one should be aware that reliability of results obtained by both linear and nonlinear models requires extremely high accuracy of NO and flow measurements. At high end of the flows the short time for measurement makes flow measurement challenging. There might also be a problem of NO measurement accuracy because of typical concentrations which are then only a few ppbs. At the low end of the flows the subjects might have difficulties in maintaining the flow constant; however, the effect of axial diffusion is theoretically remarkable, but very difficult to be corrected on an individual basis. Nitric oxide parameters from linear and nonlinear models generated by multiple flow rates are shown in table 4.
Most interesting results from the use of the nonlinear model are that in atopy the D aw NO is increased which explains the increase in exhaled NO in rhinitis [96] , without increase in C aw NO [74] . In atopic asthma, when inflammation is also present, there is an increase in C aw NO as well as D aw NO [74] . Treatment with inhaled corticosteroids will only affect the C aw NO and not D aw NO [11, 67] . In a study done on asthmatic children it was found that C aw NO was increased three-fold [97] . Dividing these asthmatic children into two groups, i.e. with treatment and without treatment, presented similar F E NO values, 55 and 56 ppb, respectively. Applying the nonlinear model, differences could be shown, such as higher D aw NO in the treated group and lower C aw NO due to non-treatment [9] . Therefore it would be interesting to test if C aw NO could be used for guiding inhaled corticosteroids [67] , instead of F E NO, which has not been successful [73] . In non-atopic asthma neither D aw NO nor C aw NO is increased [75] , which is in line with old findings that exhaled NO did not differ from control subjects [76] . In COPD two distinct groups have been identified, one with increased D aw NO such as in atopic asthma and one group with very low levels of D aw NO [74] . Further investigations have to be carried out in order to see if these Table 4 . Nitric oxide parameters from linear and nonlinear models generated by multiple flow rates. With the linear model an additional exhalation is needed for the F E NO 0.05 , while the nonlinear model can calculate the corresponding value.
Range of flow
No. of Model rates (ml s groups represent different phenotypes in COPD, which can result in altered treatment.
Conclusion and future outlook
Several types of sensors for monitoring NO in exhaled breath were presented. Generally, a sensor should provide fast, sensitive and selective NO measurements and be available at low cost. Additionally, for several clinical applications allowing multiple flow sampling rates is desired. Each existing technology fulfils most of the mentioned criteria, but not all. Therefore it is important to review the clinical application information carefully before deciding on the best suited technology. The chemiluminescence instruments are expensive, and not user friendly for use in clinical research and clinical practice. The electrochemical instruments too are set for one flow sampling; have questionable reproducibility, although according to some authors it is clinically accepted (up to 10 ppb); and high running costs. Due to their small size they were tested in general practice and by patients at home. In contrast, the laser-based sensors are slowly penetrating the clinical area, being carefully developed to overcome the drawbacks of the two aforementioned technologies. This technology may offer additional advantage by measuring simultaneously the exhaled CO 2 which is required to follow the different phases of exhalation. Modelling NO release from the lung will provide additional information about the individual patient status and increase our understanding about the role of NO in the pathophysiology of different lung diseases. There is a need for further studies with large cohorts to be followed over the years to get better insights into the importance of using low NO flow for the re-modelling of the airways. The NO parameters can guide the clinician in choosing the optimal treatment and then calculate the personal best F E NO to be monitored with a NO device in a primary care setting or at home. However, to be able to compare results of NO parameters from different population studies it is of vital importance to follow the flow limits in the NO models. With the use of lower flow rates than recommended for the linear model, calculation of the NO parameters will be incorrect, high C A NO with a low J aw NO. A single correction factor for axial back diffusion will not solve this problem.
Without doubts, monitoring exhaled NO has a significant contribution in disease diagnosis and monitoring treatment efficiency, especially in asthma and some lung-related diseases. The knowledge of NO biology achieved was used to provide guidelines for NO measurements. A proper selection of the clinical scenarios in combination with a proper methodology for monitoring NO that includes a suitable detection method in combination with a trustable standardization procedure and proper determination of the NO parameters will definitely improve the confidence in using exhaled NO in other clinical applications.
